Trulieve Cannabis Corp.

TRLV Healthcare Drug Manufacturers Specialty & Generic

Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.

Revenue
−20.1%
EPS
−2,391.1%
Free cash flow
+24.5%
Total debt
−37.0%

Quarter to September 2026, against a year earlier

11.54 0.64 +5.87%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−5.6×
Dividend yield
—
F-score
6/9
Altman Z
0.98
Beneish M
−2.99
Dividend safety
n/a
Sep '26 From the 10-Q filed 5 Nov Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
4 5 5 6

+8 more TTM periods

ROE
(45.52%) (47.92%) (6.85%) (9.73%)
ROA
(17.61%) (18.93%) (2.86%) (4.18%)
ROIC
0.00% (21.87%) 7.77% 7.61%
Return on Tangible Assets
(42.29%) (44.92%) (6.73%) (10.52%)
Average Days of Receivables
0.00 8.66 6.49 5.86
Free Cash Flow per Share
1.26 0.97 1.16 1.11
Free Cash Flow
242.48 186.25 224.20 212.31
Capital Expenditures
— (58.20) (53.20) (60.51)
Other line items
Cash ROIC
31.43% 12.97% 12.04% 12.56%
Accounts Receivable Turnover
0.00 50.51 58.96 63.42
Accounts Payable Turnover
5.69 6.57 5.55 5.32
Inventory Turnover
1.96 2.16 1.96 1.98
Average Days of Payables
58.49 48.62 61.02 64.19
Days of Inventory on Hand
163.69 147.75 187.33 188.16
Tax Rate
0.36 0.44 (1.84) (2.28)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
38.93% 37.93% 36.86% 37.69%
Share Based Compensation of Revenue
1.94% 1.83% 1.77% 1.73%
Interest Coverage
0.00 (4.84) 2.38 2.26
Operating CF/Net income
(0.54) (0.52) (3.42) (2.34)
Depreciation/Fixed assets
0.00 0.29 0.26 0.26
Capex/Depreciation
— (0.34) (0.31) (0.35)
Revenue per Share
5.60 5.91 6.08 6.17
Operating CF per Share
1.26 1.27 1.44 1.43
Capex per Share
0.00 (0.30) (0.28) (0.32)
Capex to Sales
0.00 0.05 0.05 0.05

Fold the line items

Columns are period end dates · fundamentals updated 5 Nov 2026